LitAlert ~~ GeneLit.com

    • Intrafamilial communication of hereditary breast and ovarian cancer genetic information in Italian women: towards a personalised approach.
    • Di Pietro ML, Zaçe D, Orfino A, Di Raimo FR, Poscia A, de Matteis E, Turchetti D, Godino L, Beronazzi B, Franiuk M, Bruzzone C, Varesco L, Lucci-Cordisco E, Genuardi M.
    • Eur J Hum Genet. 2020 Sep 14. doi: 10.1038/s41431-020-00723-7. Epub ahead of print.
    • The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
    • Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL.
    • Int J Gynecol Cancer. 2020 Sep 14:ijgc-2020-001789. doi: 10.1136/ijgc-2020-001789. Epub ahead of print.
    • Review
    • BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    • Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.
    • EBioMedicine. 2020 Sep 11;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub ahead of print.
    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • Integrative Review of Reproductive Decision Making of Women Who Are BRCA Positive.
    • Skrovanek E, Dunbar-Jacob J, Dunwoody C, Wesmiller S.
    • J Obstet Gynecol Neonatal Nurs. 2020 Sep 11:S0884-2175(20)30117-9. doi: 10.1016/j.jogn.2020.07.006. Epub ahead of print.
    • Review
    • Splicing Enhancers at Intron-Exon Borders Participate in Acceptor Splice Sites Recognition.
    • Kovácová T, Soucek P, Hujová P, Freiberger T, Grodecká L.
    • Int J Mol Sci. 2020 Sep 8;21(18):E6553. doi: 10.3390/ijms21186553.
    • Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
    • Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
    • Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
    • Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.
    • Silva Filho ALD, Carvalho GM, Sena LC, Gomes LPG, Valério MFH, Martins RIL, Cândido EB.
    • Rev Assoc Med Bras (1992). 2020 Aug;66(8):1134-1138. doi: 10.1590/1806-9282.66.8.1134.